Literature DB >> 21797800

Serum gamma-glutamyl transferase (GGT) levels and inflammatory activity in patients with non-dipper hypertension.

Necip Ermis1, Julide Yagmur, Nusret Acikgoz, Mehmet Cansel, Bilal Cuglan, Hasan Pekdemir, Ramazan Ozdemir.   

Abstract

Non-dipper hypertension is associated with increased cardiovascular morbidity and mortality. We aimed to evaluate serum gamma-glutamyl transferase (GGT) level, which is accepted as a marker for oxidative stress and its relationship with inflammatory activity in patients with non-dipper hypertension. Age and sex matched 43 dipper hypertensive patients, 40 non-dipper patients, and 46 healthy subjects were included into the study. Serum GGT and C-reactive protein (CRP) levels were measured and compared between each of the groups. Serum GGT activity was higher in the non-dipper and the dipper hypertensive groups than in the control group (33.5 ± 11.8 and 28.1 ± 10.1 U/l, respectively, vs. 21.2 ± 6.5 U/l; p < 0.001). There was a statistically significant difference in serum GGT activity between the non-dippers and the dippers (p = 0.021). When compared with the control group, serum CRP levels were significantly increased in both the non-dipper and the dipper hypertensive groups (6.1 ± 2.6 and 5.4 ± 2.1 mg/l, respectively, vs. 2.8 ± 1.7 mg/L; p < 0.001). Increased CRP levels were higher in non-dippers than dippers (p = 0.046). A significant correlation was found between GGT and CRP measurements (r = 0.37, p = 0.002). Serum GGT levels, which are markers of the oxidative stress and CRP levels, are both increased in non-dipper hypertension. Increased GGT activity, found to be correlated with CRP levels, may be one of the reasons behind the non-dipper hypertension related cardiovascular complications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21797800     DOI: 10.3109/10641963.2011.577485

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  7 in total

1.  Evaluation of plasma chemerin levels in patients with non-dipper blood pressure patterns.

Authors:  Murat Meric; Korhan Soylu; Bahattin Avci; Serkan Yuksel; Okan Gulel; Mustafa Yenercag; Metin Coksevim; Adem Uzun
Journal:  Med Sci Monit       Date:  2014-04-28

2.  Increased risk of acute pancreatitis occurrence in smokers with rs5751901 polymorphisms in GGT1 gene.

Authors:  Milena Ściskalska; Monika Ołdakowska; Grzegorz Marek; Halina Milnerowicz
Journal:  Int J Med Sci       Date:  2020-01-14       Impact factor: 3.738

3.  Serum uric acid, inflammation, and nondipping circadian pattern in essential hypertension.

Authors:  Osman Turak; Fırat Ozcan; Derya Tok; Ahmet Işleyen; Erdoğan Sökmen; Irfan Taşoğlu; Sinan Aydoğdu; Nihat Sen; Kim McFann; Richard J Johnson; Mehmet Kanbay
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-11-02       Impact factor: 3.738

Review 4.  Antihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently?

Authors:  Chakrapani Mahabala; Padmanabha Kamath; Unnikrishnan Bhaskaran; Narasimha D Pai; Aparna U Pai
Journal:  Vasc Health Risk Manag       Date:  2013-03-24

5.  Sphingomyelin levels in nondipper and dipper hypertensive patients.

Authors:  Huan Zheng; Xiaoyun Xie; Nanzi Xie; Huifeng Xu; Junling Huang; Ming Luo
Journal:  Exp Ther Med       Date:  2013-12-19       Impact factor: 2.447

6.  The association of serum gamma-glutamyl transpeptidase level and other laboratory parameters with blood pressure in hypertensive patients under ambulatory blood pressure monitoring.

Authors:  Adile Ortakoyluoglu; Betul Boz; Oguzhan Sıtkı Dizdar; Deniz Avcı; Ali Cetinkaya; Osman Baspınar
Journal:  Ther Clin Risk Manag       Date:  2016-09-07       Impact factor: 2.423

7.  Comparison of left atrial volume and function in non-dipper versus dipper hypertensives: A real-time three-dimensional echocardiography study.

Authors:  Necip Ermiş; Yılmaz Ömür Otlu; Abdülmecit Afşin; Şıho Hidayet; Nusret Açıkgöz; Mehmet Cansel; Jülide Yağmur; M Cengiz Çolak
Journal:  Anatol J Cardiol       Date:  2016-02-04       Impact factor: 1.596

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.